Where Your Arm Rests Can Add 6 Points to a Blood Pressure Reading
Lap: +3.9 mmHg systolic. Arm at your side: +6.5. A randomized trial measured the couch error, and the fix is a table and five quiet minutes.
Pillar
Health
Heart, metabolism, brain and sleep: what new trials and studies actually show.
24 articles
Semaglutide's Heart Benefit Is Not Just About Weight Loss
Known risk factors explain at most about half of the 20% drop in heart events, and the frailest patients still benefit. Widening eligibility to a BMI of 25 is a different question.
Orforglipron Worked Across Menopause Stages, With One Asterisk
Women lost 12.8% to 14.4% of their weight on the top dose without diabetes. The diabetes trial tells a shakier story, built partly on a subgroup of 10 women.
One Insulin Shot a Week: What the Efsitora Approval Covers
Efsitora matched daily insulin on HbA1c in four trials and trades 365 injections for 52. In type 1 diabetes, severe lows were three times as common, which is why the label stops at type 2.
Patch Pumps, Implanted Sensors and a Year of Omnipod 5 Data
Omnipod 5 users kept 4.3 extra hours a day in range for a year. Beta Bionics' Mint is cleared but launches in 2027, and its new algorithm still awaits the FDA.
Eight Hours or Nine? What Eating Window Trials Actually Show
Shorter windows meant a few more pounds lost over months. Against a dietitian, a 9 hour window did no better on blood sugar, and both groups lost the same weight.
Half of Young Adults in RESET Put Type 2 Diabetes in Remission
27 of 50 reached remission in 24 weeks, against 2 of 46 on usual care, and they lost fat without losing lean mass. A 1.6 million patient study shows the stakes of waiting.
An AI Epilepsy Monitor Learned From Patients. False Alarms Fell 77.8% in a Replay
Patient feedback retrained a seizure detector and cut false alarms by a median 77.8% in 13 inpatients. The retraining was tested in a replay, not live.
Can Brain Training Delay Dementia? A 20 Year Trial, Read Closely
One arm of a 1990s trial saw fewer dementia diagnoses over 20 years. Five others did not, and the statistics are being argued in public.
Strokes Before 55 Nearly Doubled. Heart Attacks Went the Other Way
Cincinnati counted 2,076 first strokes in adults under 55: the rate rose from 34 to 62 per 100,000. In Oxford, young heart attacks fell over the same years.
Lp(a): The Heart Risk Factor Science Still Can't Treat
Pelacarsen lowered Lp(a) in 8,323 HORIZON patients, but heart attacks and strokes did not fall. Why that gap between biomarker and outcome matters.
Diet Soda Matched Water for Weight. The Word “Equivalent” Didn’t
In the SWITCH trial, diet drinkers lost 4.8 kg in two years and water drinkers 3.7 kg, but the way it proved sameness is the real lesson.
Helping Others Slowed Cognitive Decline in People Carrying the Alzheimer's Risk Gene
A free behavior, a few hours a week, and a slower slope of decline for the gene that usually steepens it. The data are observational, and the paper says so.
The First PCSK9 Pill Is Here. The Proof Still Comes From a Shot
A daily tablet now cuts LDL by more than half, while the injectable version of the same drug class was linked to 20% fewer deaths in people with no prior heart attack.
Your Sleep Tracker Knows How Long You Slept. Not How Deeply
Every tracker in the lab studies could tell when people were asleep; none could reliably say how deeply, least of all in older adults and patients.
Retatrutide Takes Weight Off. Viking Bets a Monthly Shot Keeps It
Retatrutide's 20.8% assumes nobody quit, and Viking's 90% comes from a group of 11. The numbers behind the two biggest obesity drug headlines of September.
Deep Sleep and Alzheimer's: What Two New Studies Can and Can't Say
As tau builds in healthy older brains, deep sleep waves stop traveling and memory slips. A strong signal, but nobody yet knows which comes first.
Aprocitentan: Another Dial for Hard to Control Blood Pressure
Against placebo, the endothelin blocker lowered systolic pressure by about 4 mmHg on top of three drugs. New post hoc data on obesity and kidney risk.
CagriSema and EloraTZP Both Beat Tirzepatide. Read the Doses
Novo won at the low end of the dose range, 12.4 versus 9.1 percent. Lilly won at the top, 23.3 versus 14.8, and lost up to one patient in four to side effects.
The Lp(a) Test Everyone Should Get Once, and What It Can't Tell You
One blood test for life sounds simple, but this year's research shows the result can move, the risk has no clean cutoff, and no Lp(a) drug has proven it saves hearts.
A GLP-1 Pill Against Insulin: What ACHIEVE-4 Proved for the Heart
Orforglipron cleared a heart safety bar against insulin glargine, 4.2 versus 5.0 percent, and posted a mortality gap the trial was never built to prove.
The Pill Duel: Orforglipron Beats Oral Semaglutide Head to Head
ACHIEVE-3, 1,698 adults, 52 weeks: in the primary analysis HbA1c fell 1.91 points against 1.47. A real head to head, run by one of the duelists.
The Race to Keep Muscle on GLP-1s Reaches Phase 2
Sironax's FORGE-LM trial is half enrolled. The endpoint is body composition, which is the right question. Enrollment, though, is not a result.
Your Body Clock Leaves a Signature on Your Wrist
809 adults, seven days of wrist sensors: robust temperature rhythms tracked with better metabolic markers, light with lower triglycerides. Association only.
Get Facts First, every Sunday
One email a week: the 5 facts that mattered in AI, health and longevity, each checked against the original source. No spam. Unsubscribe in one click.
By subscribing you agree to receive the newsletter. See the privacy policy.